نتایج جستجو برای: vemurafenib
تعداد نتایج: 1054 فیلتر نتایج به سال:
Vemurafenib, a RAF inhibitor, extends survival in patients with BRAF V600 -mutant melanoma but activates extracellular signal–regulated kinase (ERK) signaling in RAS-mutant cells. In a patient with a BRAF V600K -mutant melanoma responding to vemurafenib, we observed accelerated progression of a previously unrecognized NRAS-mutant leukemia. We hypothesized that combining vemurafenib with a MAP–E...
Since the FDA approval of vemurafenib for the treatment of disseminated melanoma in 2011, followed by approval of dabrafenib in 2013 and dabrafenib/trametinib combination in 2014, melanoma has become the poster child for targeted kinase therapy. Despite encouraging initial clinical responses, most patients ultimately develop drug resistance and relapse, prompting an enormous research effort foc...
Mutations of the serine/threonine-protein kinase BRAF protein are found in 80% of melanomas. Vemurafenib (Zelboraf, Genentech/Daiichi Sankyo), a specific inhibitor of BRAF, was approved by the FDA for metastatic melanoma in August 2011. Dabrafenib (GlaxoSmithKline, GSK 2118436), tested in the BREAK-2 trial, demonstrated a 59% confirmed response rate with a median progression-free survival (PFS)...
BACKGROUND Kinase inhibitors targeting the BRAF V600 mutation have become standard in the treatment of metastatic melanoma. Albeit in wide clinical use, the patterns associated with therapy outcome are not fully elucidated. The present study was aimed to identify predictive factors of therapy response and survival under the BRAF inhibitor vemurafenib. PATIENTS AND METHODS This multicenter ret...
Large-scale, unbiased combinatorial drug screening has been used to identify effective genotype-selective therapeutic combinations that show promising activity in preclinical models of mutant BRAF andRAS melanoma that are resistant to the clinical BRAF inhibitor vemurafenib.
In this issue of Blood, Dietrich et al report that the low-dose BRAF inhibitor, vemurafenib, is highly effective in refractory hairy cell leukemia. Despite enormous progress that has been made with purine nucleoside analogs as the initial treatment of patients with hairy cell leukemia, the relapse rate and eventual development of refractory disease mandate the continued search for effective new...
IMPORTANCE The cutaneous adverse effects of the BRAF inhibitors vemurafenib and dabrafenib mesylate in the treatment of metastatic melanoma have been well reported. The addition of a MEK inhibitor to a BRAF inhibitor improves the blockade of the mitogen-activated protein kinase pathway. The combination of dabrafenib with the MEK inhibitor trametinib dimethyl sulfoxide (CombiDT therapy) increase...
Acquired resistance to second generation BRAF inhibitors (BRAFis), like vemurafenib is limiting the benefits of long term targeted therapy for patients with malignant melanomas that harbor BRAF V600 mutations. Since many resistance mechanisms have been described, most of them causing a hyperactivation of the MAPK- or PI3K/AKT signaling pathways, one potential strategy to overcome BRAFi resistan...
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید